[go: up one dir, main page]

ATE496990T1 - Verfahren zur herstellung von plasmid dns in pharmazeutischer qualität - Google Patents

Verfahren zur herstellung von plasmid dns in pharmazeutischer qualität

Info

Publication number
ATE496990T1
ATE496990T1 AT05739527T AT05739527T ATE496990T1 AT E496990 T1 ATE496990 T1 AT E496990T1 AT 05739527 T AT05739527 T AT 05739527T AT 05739527 T AT05739527 T AT 05739527T AT E496990 T1 ATE496990 T1 AT E496990T1
Authority
AT
Austria
Prior art keywords
plasmid dna
producing pharmaceutical
pharmaceutical quality
order
purification steps
Prior art date
Application number
AT05739527T
Other languages
English (en)
Inventor
Francis Blanche
Michel Couder
Nicolas Maestrali
Thierry Guillemin
David Gaillac
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE496990T1 publication Critical patent/ATE496990T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10Protozoa; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2303/00Specific treatment goals
    • C02F2303/06Sludge reduction, e.g. by lysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05739527T 2004-04-19 2005-04-19 Verfahren zur herstellung von plasmid dns in pharmazeutischer qualität ATE496990T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56300804P 2004-04-19 2004-04-19
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna

Publications (1)

Publication Number Publication Date
ATE496990T1 true ATE496990T1 (de) 2011-02-15

Family

ID=40635654

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05739527T ATE496990T1 (de) 2004-04-19 2005-04-19 Verfahren zur herstellung von plasmid dns in pharmazeutischer qualität

Country Status (16)

Country Link
US (1) US20070213289A1 (de)
JP (2) JP2007532123A (de)
KR (1) KR20060135062A (de)
CN (2) CN101006170A (de)
AT (1) ATE496990T1 (de)
AU (2) AU2005233309B2 (de)
BR (1) BRPI0509490A (de)
CA (1) CA2559368A1 (de)
DE (1) DE602005026113D1 (de)
DK (1) DK1737945T3 (de)
EA (1) EA010576B1 (de)
MX (1) MXPA06011568A (de)
NO (1) NO20065290L (de)
NZ (1) NZ549835A (de)
WO (1) WO2005100542A1 (de)
ZA (1) ZA200607622B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101006170A (zh) * 2004-04-19 2007-07-25 森特利昂公司 纯化质粒dna的方法
EP2153260B1 (de) * 2007-05-23 2017-01-25 VGXI, Inc. Zusammensetzung mit einer hohen konzentration an biologisch aktiven molekülen und verfahren zu ihrer herstellung
US8647857B2 (en) 2008-04-30 2014-02-11 Gradalis, Inc. Processes for the digestion of colanic acid
US8491792B2 (en) 2010-01-15 2013-07-23 Board Of Regents, The University Of Texas System Non-dispersive process for insoluble oil recovery from aqueous slurries
US8617396B2 (en) 2010-01-15 2013-12-31 Board Of Regents, The University Of Texas System Non-dispersive process for insoluble oil recovery from aqueous slurries
CA2835930C (en) * 2010-01-15 2016-07-12 Board Of Regents, The University Of Texas System Non-dispersive process for insoluble oil recovery from aqueous slurries
US9688921B2 (en) 2013-02-26 2017-06-27 Board Of Regents, The University Of Texas System Oil quality using a microporous hollow fiber membrane
US9643127B2 (en) 2010-01-15 2017-05-09 Board Of Regents Of The University Of Texas System Simultaneous removal of oil and gases from liquid sources using a hollow fiber membrane
US9782726B2 (en) 2010-01-15 2017-10-10 Board Of Regents, The University Of Texas System Non-dispersive process for oil recovery
US9149772B2 (en) 2010-01-15 2015-10-06 Board Of Regents, The University Of Texas Systems Enhancing flux of a microporous hollow fiber membrane
US20130115598A1 (en) * 2011-10-13 2013-05-09 Lawrence Loeb Oligonucleotide probe retrieval assay for dna transactions in mammalian cells
GB2497575A (en) * 2011-12-15 2013-06-19 Protein Technologies Ltd Cell lysis in a flowing liquid using a lytic agent
WO2013188849A1 (en) 2012-06-14 2013-12-19 Board Of Regents, The University Of Texas System Non-dispersive oil recovery from oil industry liquid sources
EP2682168A1 (de) 2012-07-02 2014-01-08 Millipore Corporation Reinigung biologischer Moleküle
CN104370997B (zh) * 2014-09-24 2018-07-31 陈辉 去除生物制品中细菌内毒素的试剂盒、方法及其生物制品的制备方法
CN106884011B (zh) * 2015-12-16 2020-11-17 固安鼎泰海规生物科技有限公司 一种规模化质粒纯化的联合液相层析分离方法
WO2017186815A1 (en) * 2016-04-26 2017-11-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for enhanced expression of frataxin
EP3468981B1 (de) * 2016-06-14 2024-07-24 Biogen MA Inc. Verfahren zur reinigung von oligonukleotiden unter verwendung von hydrophober chromatographie
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
GB201710130D0 (en) 2017-06-26 2017-08-09 Ge Healthcare Bioprocess R & D Ab A Method of seperation
EP3673990A4 (de) * 2017-08-25 2021-05-05 Sekisui Medical Co., Ltd. Chromatographiepackung zur trennung und/oder detektion von methylierter dna
CN108531563A (zh) * 2018-02-05 2018-09-14 深圳市尚维高科有限公司 多孔微球的用途及裂解液以及裂解液的使用方法
CN110348090B (zh) * 2019-06-28 2021-05-04 浙江大学 基于人工神经网络实现多柱连续流层析设计及分析的方法
CN111088248B (zh) * 2019-12-23 2020-10-16 广州湾区生物科技有限公司 一种用于提取无内毒素质粒的磁性材料及其使用方法
CN111394427B (zh) * 2020-04-22 2023-04-11 宁波市博坤生物科技有限公司 一种含泥土检材中微量dna的提取方法
CN112798697B (zh) * 2020-11-16 2022-11-22 武汉波睿达生物科技有限公司 慢病毒包装系统辅助质粒的超螺旋结构纯度的检测方法
CN115404154A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的装置
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
WO2023025208A1 (zh) * 2021-08-24 2023-03-02 赛斯尔擎生物技术(上海)有限公司 一种修饰细胞的方法
CN114085828A (zh) * 2021-11-17 2022-02-25 安徽荃银高科种业股份有限公司 一种水稻基因组dna的快速低成本提取方法及其应用
WO2023095665A1 (ja) * 2021-11-29 2023-06-01 東ソー株式会社 抗体の分離方法
EP4234695A1 (de) * 2022-02-24 2023-08-30 Sartorius BIA Separations d.o.o. Verfahren zur selektiven entfernung von verunreinigungen während eines verfahrens zur reinigung von biologischen mitteln
CN116987581A (zh) * 2023-08-08 2023-11-03 江苏耀海生物制药有限公司 一种质粒dna制备装置及制备工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
FR2728264B1 (fr) * 1994-12-16 1997-01-31 Rhone Poulenc Rorer Sa Purification d'adn par formation de triple helice avec un oligonucleotide immobilise
WO1997023601A1 (en) * 1995-12-21 1997-07-03 Genzyme Corporation Method for lysing cells
FR2746412B1 (fr) * 1996-03-21 1998-06-12 Rhone Poulenc Rorer Sa Purification d'adn plasmidique de qualite pharmaceutique
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (fr) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Procede et dispositif de lyse de bacteries
MXPA01012213A (es) * 1999-05-28 2003-06-24 Bio Science Contract Productio Metodos de purificacion de adn y adn purificado.
DE60132200T2 (de) * 2000-05-26 2008-12-18 Centelion Reinigung einer tripelhelixformation mittels eines immobilisierten oligonukleotides
US7011791B2 (en) * 2000-09-18 2006-03-14 University Of Washington Microfluidic devices for rotational manipulation of the fluidic interface between multiple flow streams
US20040002081A1 (en) * 2001-12-18 2004-01-01 Boehringer Ingelheim International Gmbh And Bia Separations D.O.O. Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale
ATE420167T1 (de) * 2002-12-23 2009-01-15 Vical Inc Reinigungsverfahren für plasmid-dna
PT1664277E (pt) * 2003-09-17 2012-01-17 Aventis Pharma Sa Método de preparação de adn plasmídico de grau farmacêutico
CN101006170A (zh) * 2004-04-19 2007-07-25 森特利昂公司 纯化质粒dna的方法

Also Published As

Publication number Publication date
EA010576B1 (ru) 2008-10-30
DE602005026113D1 (de) 2011-03-10
NZ549835A (en) 2008-12-24
CA2559368A1 (en) 2005-10-27
CN101006170A (zh) 2007-07-25
AU2005233309A1 (en) 2005-10-27
US20070213289A1 (en) 2007-09-13
NO20065290L (no) 2006-11-17
JP2011132249A (ja) 2011-07-07
ZA200607622B (en) 2008-05-28
WO2005100542A1 (en) 2005-10-27
KR20060135062A (ko) 2006-12-28
JP2007532123A (ja) 2007-11-15
BRPI0509490A (pt) 2007-09-11
MXPA06011568A (es) 2006-12-20
AU2011200978A1 (en) 2011-04-07
DK1737945T3 (da) 2011-05-09
CN102031258A (zh) 2011-04-27
AU2005233309B2 (en) 2011-03-31
EA200601728A1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
ATE496990T1 (de) Verfahren zur herstellung von plasmid dns in pharmazeutischer qualität
ATE532853T1 (de) Verfahren zur herstellung einer plasmid-dna in pharmazeutischer qualität
PL356771A1 (en) Magnetic glass particles, method for their preparation and uses thereof
GB2575930A (en) Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2007017229A3 (de) Verfahren für die kontinuierliche zielgerichtete evolution von proteinen in vitro
WO2005059097A3 (en) Methods for high fidelity production of long nucleic acid molecules
EP2615112A3 (de) Gereinigte Immunoglobulinfusionsproteine und Verfahren zu deren Reinigung
WO2005010150A3 (en) Method for in vitro selection of 2’-substituted nucleic acids
WO2003040687A3 (en) Isolation and purification of nucleic acids
ATE493506T1 (de) Zusammensetzung und verfahren zur herstellung von nukleinsäuren aus sputum
WO2007117438A3 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
UA94206C2 (ru) Бактериальные факторы вирулентности и варианты их применения
FR2804971B1 (fr) Adn codant une acetohydroxyacide synthase, bacterie le contenant et procede de production de l-valine par culture de cette bacterie
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
CY1111401T1 (el) Μεθοδος καθαρισμου πλασμιδιακου dna
ATE371731T1 (de) Verfahren zur skalierbaren reinigung von plasmid- dns
WO2004081166A3 (de) Nukleotidsequenzen coryneformer bakterien codierend für am l-serinstoffwechsel beteiligte proteine sowie verfahren zur mikrobiellen herstellung von l-serin
ATE451457T1 (de) Verfahren zur dipeptidherstellung
ATE553194T1 (de) Verfahren zur dipeptidherstellung
PT1630232E (pt) Sequências de nucleótidos optimizadas que codificam sgp130
ATE332971T1 (de) Typ ii dns polymerase aus pyrococcus abyssi
WO2006055040A3 (en) Identification of proteins in a genome
WO2021231549A3 (en) Engineered gene-editing proteins
WO2006081529A3 (en) Compositions and processes for improved plasmid dna production
WO2005072092A3 (en) Systems for tightly regulated gene expression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1737945

Country of ref document: EP